PDL BioPharma, Inc.; A Genentech/Roche Buyout Candidate?
Seeking Alpha -- PDL BioPharma (PDLI) is a very unique biotech company owns a portfolio of valuable patents that bring in royalties from licensed products. Genentech/Roche (RHHBY.PK) currently has 4 marketed drugs licensing PDLI's technology: Herceptin, Avastin, Lucentis and Xolair. PDLI collects royalties from the total world-wide sales of these successful drugs at rates ranging from 1% to 3%.